Table 3.

Changes in Patient-Centered Outcomes and Incidence of Selected Multidrug-Resistant Organisms After the Implementation of Postprescription Review and Feedback

Patient-Centered Outcome	Baseline Trend in the Preintervention Period (95% CI)	P	Slope Change in the Intervention Period (95% CI)	P	Change in slope (95% CI)	P
Incidence of CDI per 10000 patient-days	−0.01 (−0.08 to 0.05)	.67	0.01 (−0.02 to 0.04)	.41	0.03 (−0.05 to 0.10)	.46
Average length of hospital stay	0.01 (−0.02 to 0.36)	.46	−0.03 (−0.04 to −0.02)	<.001	−0.04 (−0.07 to −0.17)	.002
Average monthly mortality rate	0.15 (−0.15 to 0.45)	.15	−0.01 (−0.02 to 0.01)	.73	−0.02 (−0.05 to 0.17)	.32
Incidence of MRSA per 1000 patient-days	−0.004 (−0.01 to 0.003)	.25	−0.001 (−0.004 to 0.001)	.28	0.002 (−0.005 to 0.01)	.50
Incidence of ESBL per 1000 patient-days	0.001 (−0.006 to 0.007)	.89	0.003 (−0.001 to 0.006)	.09	0.002 (−0.005 to 0.009)	.59

Abbreviations: CDI, Clostridium difficile infection; ESBL, extended-spectrum β lactamase; MRSA, methicillin-resistant Staphylococcus aureus.